Inventprise, a clinical-stage vaccine company, published preclinical study results in Vaccine Journal demonstrating the potential of their bivalent SARS-CoV-2 conjugate vaccine to offer broad and durable protection against evolving COVID-19 variants. The 18-month study, completed in late 2023, utilized Inventprise’s proprietary linker protein conjugation technology to stimulate both B-cell and T-cell immunity. This approach differs from existing mRNA vaccines by aiming to induce long-lasting immunity.
This research could significantly impact the fight against COVID-19 by potentially offering a longer-lasting solution. The prospect of reduced reliance on frequent booster shots addresses a critical challenge in managing the pandemic, particularly for vulnerable populations and in regions with limited healthcare infrastructure. The development also suggests broader applicability of the conjugate platform for other infectious diseases requiring durable immunity.
The vaccine conjugates a detoxified diphtheria-derived carrier protein to SARS-CoV-2 Beta and Delta strain surface proteins. Preclinical models demonstrated broad neutralizing antibody responses across up to five variants, activation of both humoral and cellular immunity, including memory T-cell formation, and the theoretical potential for extended protection, possibly eliminating the need for boosters. While the study’s timeframe didn’t fully confirm the duration of immunity, data indicates this conjugate approach could overcome limitations of current mRNA vaccine strategies.
This development marks a potentially substantial advancement in vaccine technology. The findings suggest a pathway towards more sustainable and equitable global immunization strategies. Inventprise’s pursuit of funding and partnerships to advance this research could accelerate its translation into a viable vaccine candidate, contributing meaningfully to public health preparedness for existing and future viral threats.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
